CORBF Quote, Financials, Valuation and Earnings

Hong Kong Pharma Digital Technology Holdings has a net margin of -- compared to Global Cord Blood's net margin of --. Global Cord Blood's return on equity of -- beat Hong Kong Pharma Digital Technology Holdings's return on equity of --.

Global Cord Blood has a consensus price target of --, signalling downside risk potential of --. On the other hand Hong Kong Pharma Digital Technology Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Global Cord Blood has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe Global Cord Blood is more attractive than Hong Kong Pharma Digital Technology Holdings.

Global Cord Blood has a beta of -0.677, which suggesting that the stock is 167.74% less volatile than S&P 500. In comparison Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Global Cord Blood has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hong Kong Pharma Digital Technology Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood pays -- of its earnings as a dividend. Hong Kong Pharma Digital Technology Holdings pays out -- of its earnings as a dividend.

Global Cord Blood quarterly revenues are --, which are smaller than Hong Kong Pharma Digital Technology Holdings quarterly revenues of --. Global Cord Blood's net income of -- is lower than Hong Kong Pharma Digital Technology Holdings's net income of --. Notably, Global Cord Blood's price-to-earnings ratio is -- while Hong Kong Pharma Digital Technology Holdings's PE ratio is 5.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood is 0.67x versus 0.53x for Hong Kong Pharma Digital Technology Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Prenetics Global has a net margin of -- compared to Global Cord Blood's net margin of -137.21%. Global Cord Blood's return on equity of -- beat Prenetics Global's return on equity of -23.16%.

Global Cord Blood has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $13.00 which suggests that it could grow by 144.6%. Given that Prenetics Global has higher upside potential than Global Cord Blood, analysts believe Prenetics Global is more attractive than Global Cord Blood.

Global Cord Blood has a beta of -0.677, which suggesting that the stock is 167.74% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Global Cord Blood has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.

Global Cord Blood quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Global Cord Blood's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Global Cord Blood's price-to-earnings ratio is -- while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood is 0.67x versus 2.17x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.

Regencell Bioscience Holdings has a net margin of -- compared to Global Cord Blood's net margin of --. Global Cord Blood's return on equity of -- beat Regencell Bioscience Holdings's return on equity of --.

Global Cord Blood has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Global Cord Blood has higher upside potential than Regencell Bioscience Holdings, analysts believe Global Cord Blood is more attractive than Regencell Bioscience Holdings.

Global Cord Blood has a beta of -0.677, which suggesting that the stock is 167.74% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Global Cord Blood has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.

Global Cord Blood quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. Global Cord Blood's net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, Global Cord Blood's price-to-earnings ratio is -- while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood is 0.67x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Sino Biopharmaceutical has a net margin of -- compared to Global Cord Blood's net margin of --. Global Cord Blood's return on equity of -- beat Sino Biopharmaceutical's return on equity of 8.57%.

Global Cord Blood has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Global Cord Blood has higher upside potential than Sino Biopharmaceutical, analysts believe Global Cord Blood is more attractive than Sino Biopharmaceutical.

Global Cord Blood has a beta of -0.677, which suggesting that the stock is 167.74% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.486, suggesting its less volatile than the S&P 500 by 51.441%.

Global Cord Blood has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical offers a yield of 2.08% to investors and pays a quarterly dividend of $0.00 per share. Global Cord Blood pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out 52.76% of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Global Cord Blood quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. Global Cord Blood's net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, Global Cord Blood's price-to-earnings ratio is -- while Sino Biopharmaceutical's PE ratio is 18.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global Cord Blood is 0.67x versus 2.25x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.